EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Safety and efficacy of rituximab-free ABO incompatible kidney transplantation: a German multicenter cohort study

Ulrich Pein, Klemens Budde, Lutz Liefeldt, Anja Gäckler, Rolf Weimer, Hristos Karakizlis, Claudia Sommerer, Louise Benning, Christine Kurschat, Dirk Stippel, Ana Harth, Julia Weinmann-Menke und 5 weitere

Frontiers in Nephrology · 17.07.2026 · 6

DOI: 10.3389/fneph.2026.1899385 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Frontiers in Nephrology, online erschienen am 17.07.2026. Verfasst von Ulrich Pein und 16 weiteren Autor:innen. Beteiligte Einrichtung: Martin-Luther-University Halle-Wittenberg, University Hospital Halle (Saale), Department of Nephrology, Halle, Germany. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ABO-incompatible living kidney transplantation (ABOi-LKT) has become an established procedure with long-term patient and graft survival comparable to ABO-compatible transplantation. However, intensified immunosuppression increases the risk of severe infectious complications, particularly in the early post-transplant period. This study investigated whether ABOi-LKT in patients with low baseline anti-ABO isoagglutinin titers can be performed safely without rituximab and thereby reduce infectious complications.

Methods

In this multicenter retrospective cohort study, recipients of ABOi-LKT with low pretransplant anti-ABO titers (≤1:16) were compared according to rituximab use. Clinical outcomes, graft function, rejection episodes, surgical complications, and infectious events were analyzed.

Results

Eleven German transplant centers identified 46 patients who underwent ABOi-LKT without rituximab between 2016 and 2024 and 85 low-titer recipients who received rituximab (single dose 375 mg/m²). Baseline characteristics and median pretransplant anti-ABO titers (1:2) were comparable between groups. Patients underwent a median of two extracorporeal antibody eliminations and received comparable immunosuppression. Graft function at discharge and after 3 and 12 months, as well as proteinuria, did not differ between cohorts. One graft loss due to acute antibody-mediated rejection occurred in the rituximab-free group, whereas two graft losses (one rejection, one BK polyomavirus nephropathy) and one patient death occurred in the rituximab group. Rates of surgical complications (34.8% vs. 36.5%), blood transfusions (21.7% vs. 17.6%), and rejection episodes (15% vs. 20%; p=0.499) were similar. In contrast, infectious complications were significantly more frequent among rituximab-treated patients, with a 2.4-fold increased infection risk (p=0.018). Infection-related hospitalizations occurred significantly more often in the rituximab group (64.6% vs. 31.3%; p=0.003).

Conclusions

ABOi-LKT without rituximab appears safe in recipients with low pretransplant anti-ABO titers. Short-term graft function, graft survival, patient survival, and immunological outcomes were comparable to rituximab-based desensitization. Importantly, omission of rituximab was associated with significantly fewer infectious complications and infection-related hospitalizations, supporting a tailored, lower-intensity immunosuppressive approach in selected low-risk patients.

Schlagwörter

Stichwörter der Autor:innen

ABO incompatibleinfectious complicationsliving kidney transplantationoutcomerituximab

Autor:innen und Institutionen

  • Martin-Luther-University Halle-Wittenberg, University Hospital Halle (Saale), Department of Nephrology, Halle, Germany.
  • Department of Nephrology, Charite - Universitatsmedizin Berlin, Berlin, Germany.
  • Department of Infectious Diseases and Nephrology, University Hospital Essen, Essen, Germany.
  • University of Giessen, Department of Internal Medicine, Giessen, Germany.
  • University Hospital Heidelberg, Department of Nephrology, Heidelberg, Germany.
  • Department II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.

Zitieren

APA

Pein, U., Budde, K., Liefeldt, L., Gäckler, A., Weimer, R., Karakizlis, H., Sommerer, C., Benning, L., Kurschat, C., Stippel, D., Harth, A., Weinmann-Menke, J., Koch, M., Kortus-Goetze, B., Reuter, S., Lachmann, N., & Mühlfeld, A. (2026). Safety and efficacy of rituximab-free ABO incompatible kidney transplantation: a German multicenter cohort study. Frontiers in Nephrology, 6. https://doi.org/10.3389/fneph.2026.1899385

Vancouver

Pein U, Budde K, Liefeldt L, Gäckler A, Weimer R, Karakizlis H, et al. Safety and efficacy of rituximab-free ABO incompatible kidney transplantation: a German multicenter cohort study. Frontiers in Nephrology. 2026;6. doi:10.3389/fneph.2026.1899385

BibTeX
@article{Pein2026,
  author = {Pein, Ulrich and Budde, Klemens and Liefeldt, Lutz and Gäckler, Anja and Weimer, Rolf and Karakizlis, Hristos and Sommerer, Claudia and Benning, Louise and Kurschat, Christine and Stippel, Dirk and Harth, Ana and Weinmann-Menke, Julia and Koch, Martina and Kortus-Goetze, Birgit and Reuter, Stefan and Lachmann, Nils and Mühlfeld, Anja},
  title = {Safety and efficacy of rituximab-free ABO incompatible kidney transplantation: a German multicenter cohort study},
  journal = {Frontiers in Nephrology},
  year = {2026},
  volume = {6},
  doi = {10.3389/fneph.2026.1899385}
}
Kostenlos starten →